Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations
- PMID: 22820256
- PMCID: PMC3413789
- DOI: 10.1038/nature11329
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations
Abstract
Medulloblastomas are the most common malignant brain tumours in children. Identifying and understanding the genetic events that drive these tumours is critical for the development of more effective diagnostic, prognostic and therapeutic strategies. Recently, our group and others described distinct molecular subtypes of medulloblastoma on the basis of transcriptional and copy number profiles. Here we use whole-exome hybrid capture and deep sequencing to identify somatic mutations across the coding regions of 92 primary medulloblastoma/normal pairs. Overall, medulloblastomas have low mutation rates consistent with other paediatric tumours, with a median of 0.35 non-silent mutations per megabase. We identified twelve genes mutated at statistically significant frequencies, including previously known mutated genes in medulloblastoma such as CTNNB1, PTCH1, MLL2, SMARCA4 and TP53. Recurrent somatic mutations were newly identified in an RNA helicase gene, DDX3X, often concurrent with CTNNB1 mutations, and in the nuclear co-repressor (N-CoR) complex genes GPS2, BCOR and LDB1. We show that mutant DDX3X potentiates transactivation of a TCF promoter and enhances cell viability in combination with mutant, but not wild-type, β-catenin. Together, our study reveals the alteration of WNT, hedgehog, histone methyltransferase and now N-CoR pathways across medulloblastomas and within specific subtypes of this disease, and nominates the RNA helicase DDX3X as a component of pathogenic β-catenin signalling in medulloblastoma.
Figures



References
-
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2007. Central Brain Tumor Registry of the United States; Hinsdale, IL: 2011. at < www.cbtrus.org>.
-
- Remke M, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011;29:2717–2723. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- L40 NS063706/NS/NINDS NIH HHS/United States
- U54 HG003067/HG/NHGRI NIH HHS/United States
- R01 NS046789/NS/NINDS NIH HHS/United States
- CAPMC/ CIHR/Canada
- HHMI/Howard Hughes Medical Institute/United States
- U54HG003067/HG/NHGRI NIH HHS/United States
- R01 CA105607/CA/NCI NIH HHS/United States
- P30 HD018655/HD/NICHD NIH HHS/United States
- R01CA105607/CA/NCI NIH HHS/United States
- R01 CA030002/CA/NCI NIH HHS/United States
- P01 CA050661/CA/NCI NIH HHS/United States
- R25NS070682/NS/NINDS NIH HHS/United States
- R01 CA109467/CA/NCI NIH HHS/United States
- R01 CA148699/CA/NCI NIH HHS/United States
- R01CA148699/CA/NCI NIH HHS/United States
- CA050661/CA/NCI NIH HHS/United States
- R01 CA154480/CA/NCI NIH HHS/United States
- R25 NS070682/NS/NINDS NIH HHS/United States
- R01CA109467/CA/NCI NIH HHS/United States
- P30 HD18655/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous